Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79%

Genmab A/S GMAB released results Thursday of the Phase 3 EPCORE FL-1 trial evaluating subcutaneous epcoritamab in combination with rituximab and lenalidomide (R2) versus R2 alone for adult patients with relapsed or refractory (R/R) follicular lymphoma (FL).The study met its dual primary endpoints of overall response rate (ORR) and progression-free survival (PFS), demonstrating statistically significant and clinically meaningful differences in both endpoints, reducing the risk of disease progression or death ...